surmount-1 tirzepatide non-diabetic obesity trial Demonstrates 94% Diabetes Reduction, 22% Weight Loss in SURMOUNT -1 Study SURMOUNT Clinical Trials Orals Session

To understand how semaglutide could fit into your personal health plan, we encourage you to take our free assessment quiz

Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jdar E, Kandler K, Rigas G, Wadden TA, et al

Mark Gilbert recommends that this meal plan be adjusted based on your size, sex and activity level

Higher rates of gastrointestinal adverse events compared to tirzepatide

In clinical studies, Semaglutide is shown to help patients lose an average of 20% weight*

This means the 2mg/mL concentration is not ideal for people on the highest doses unless they use a larger syringe or split the dose into two injections